Trial Profile
A prospective, pilot study to evaluate safety and efficacy of bortezomib and high-dose melphalan (Bor-HDM) conditioning regimen prior to autologous stem cell transplant (ASCT) in Japanese patients with newly diagnosed multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational
- 14 Dec 2015 New trial record